Hospital Universitario De Leon
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Hospital Universitario De Leon, research in cardiology focuses on major cardiovascular diseases such as atherosclerotic cardiovascular disease, coronary artery disease, and atrial fibrillation. These trials are largely aimed at testing new ways to prevent serious events like stroke, heart attack, and other complications.
- Preventing ischemic stroke in people with atrial fibrillation or after a recent stroke
- Lowering cardiovascular risk in patients with ASCVD and elevated lipoprotein(a)
- Evaluating new treatments to reduce major adverse cardiovascular events
- Studying antiplatelet strategies after coronary stent implantation
This area combines treatment innovation with efforts to improve long-term protection for patients at high risk of cardiovascular events.
Hemic and Lymphatic Diseases
The site also supports studies in hematologic cancers, including follicular lymphoma and marginal zone lymphoma. These trials are designed to compare treatment options and identify more effective approaches for patients with relapsed or refractory disease.
- Comparing new lymphoma treatment combinations with established therapies
- Improving outcomes for relapsed or refractory follicular lymphoma
- Improving outcomes for relapsed or refractory marginal zone lymphoma
This research reflects a focus on better disease control and more effective cancer care in hematology.
Neoplasms
Clinical trials in neoplasms at Hospital Universitario De Leon include breast cancer and endometrial cancer. The studies are exploring new endocrine-based and targeted approaches, as well as follow-up research to understand recurrence patterns over time.
- Testing new strategies to prevent breast cancer recurrence
- Evaluating treatments for early-stage ER+/HER2- breast cancer
- Studying tumor response in invasive breast cancer
- Assessing maintenance treatment options for advanced or recurrent endometrial cancer
The main goal is to refine cancer treatment and improve long-term outcomes for patients with solid tumors.
Nutritional and Metabolic Diseases
Research in nutritional and metabolic diseases includes type 2 diabetes, obesity, and overweight. These trials are evaluating new therapies that may help improve metabolic control and reduce related health risks.
- Testing treatments for adults with type 2 diabetes and excess weight
- Exploring therapies that may support weight and glucose management
- Assessing approaches that could lower long-term metabolic complications
This area highlights efforts to improve everyday disease management and reduce the burden of metabolic disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 16 therapeutic areas and 15 of 153 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 133 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 35 by active trials.
lock +34 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitario De Leon
lock Showing 1 of 88 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | Amgen Inc. | Phase III | Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 153 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 8 | Unknown | 2018-10-22 | 2026-02-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.